Pricing Log in Create free account

Monte Rosa Therapeutics, Inc. (GLUE) vs Immatics N.V. (IMTX)

Monte Rosa Therapeutics, Inc. and Immatics N.V. are both Biotechnology companies. Monte Rosa Therapeutics, Inc. and Immatics N.V. are of similar size ($924.8M and $874.5M). Monte Rosa Therapeutics, Inc. grew revenue faster over the last twelve months: −61.3% against −65.0%. Monte Rosa Therapeutics, Inc. has the higher net margin (−186.2% vs −489.4%) and the higher return on invested capital (0.00% vs −84.8%). Across the 15 metrics below, Monte Rosa Therapeutics, Inc. leads on 13 and Immatics N.V. on 2.

Valuation

Metric GLUE IMTX Biotechnology median
P/E n/m n/m 10.60
P/S 15.18 17.61 9.40
P/B 2.15 1.87 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 6.97 12.12 9.02
Earnings yield (13.35%) (29.34%) (32.88%)
Free cash flow yield (16.33%) (27.74%) (23.13%)

Profitability

Metric GLUE IMTX Biotechnology median
Gross margin 100.00% 100.00% 68.51%
Operating margin (214.46%) (536.26%) 0.00%
Net margin (186.24%) (489.35%) 0.00%
Free cash flow margin (247.98%) (488.01%) 0.00%
Return on equity (35.30%) (48.53%) (51.96%)
Return on assets (22.63%) (39.83%) (46.06%)
Return on invested capital 0.00% (84.83%) 0.00%

Growth

Metric GLUE IMTX Biotechnology median
Revenue growth (TTM) (61.26%) (64.99%) 6.76%
EPS growth (last fiscal year) 53.06% (1,313.33%) 29.88%
Revenue growth, 5-year CAGR — 11.81% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric GLUE IMTX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 10.32 7.54 4.97
Net debt to EBITDA 8.22 2.04 1.01

Dividend

Metric GLUE IMTX Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric GLUE IMTX Biotechnology median
Market cap 874.46m 924.75m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack